US equities
|
SPCX
$167.09
▲+5.11%
NVDA
$237.08
▲+1.34%
MU
$1,066.23
▼-0.81%
TSLA
$375.37
▲+1.29%
MSFT
$526.33
▲+1.70%
INTC
$117.08
▼-1.89%
SNDK
$1,721.02
▲+0.06%
META
$743.23
▲+2.08%
SPCX
$167.09
▲+5.11%
NVDA
$237.08
▲+1.34%
MU
$1,066.23
▼-0.81%
TSLA
$375.37
▲+1.29%
MSFT
$526.33
▲+1.70%
INTC
$117.08
▼-1.89%
SNDK
$1,721.02
▲+0.06%
META
$743.23
▲+2.08%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tevogen Inc. - Common Stock
(NQ:
TVGN
)
6.980
UNCHANGED
Delayed Quote
Updated: 3:59 PM EDT, Oct 2, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Tevogen Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Tevogen to Align Long-Term Stock-Based Incentive Program With Company Milestones, Including Revenue
January 29, 2026
From
Tevogen Bio Inc
Via
GlobeNewswire
FDA Reversal Sends Atara Biotherapeutics into Tailspin: Stock Plummets 67% on Second CRL for Tabelecleucel
January 14, 2026
In a stunning blow to the burgeoning field of allogeneic cell therapy, Atara Biotherapeutics (Nasdaq: ATRA) saw its market valuation evaporate this week following a second Complete Response Letter...
Via
MarketMinute
Topics
Bankruptcy
Tevogen Demonstrates Platform Scalability and Multi-Indication T Cell Pipeline Expansion in 2025
January 12, 2026
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO Donates Shares to Support Education for Underprivileged Children
December 22, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO Donates Personal Shares to Support Local Fire Department
December 19, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
December 11, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
December 09, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
December 08, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
November 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
November 05, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
November 03, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
October 29, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
October 15, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
September 25, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
September 23, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
September 19, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
September 10, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
September 09, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
September 08, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
September 04, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
September 03, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
August 27, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
August 26, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
August 25, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
August 22, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
August 19, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
August 19, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO Donates Personal Shares to Support Local Law Enforcement
August 18, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen CEO Donates Personal Shares to Support Brain Injury Recovery
August 18, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
Tevogen to Release Internal Asset Valuation; CEO Affirms Assets Are Fully Protected
August 14, 2025
From
Tevogen Bio Inc
Via
GlobeNewswire
< Previous
1
2
3
4
5
6
7
8
9
Next >
